AURKB and non-small cell lung carcinoma: Additionally, AURKB activation was associated with acquired resistance to EGFR TKIs, suggesting that AURKB should be targeted in NSCLC patients scheduled for anti-EGFR treatment but who lack resistance mutations [24].